secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010116
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M
---------------------------------------------------------------------

- Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.
- ELEVIDYS revenue Q4 $110.4M (impacted by flu and rescheduled infusions), full-year $898.7M.
- PMO franchise revenue Q4 $259.2M, full-year $965.6M; described as durable.
- CEO reconfirms ELEVIDYS annual sales floor of $500M; more detailed guidance deferred until initiatives evaluated.
- Preliminary results unaudited; final Q4/FY 2025 results expected late February 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/0001193125-26-010116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312526010116/srpt-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer